Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. International most cancers statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2024;74:229–63.
Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC, Han PKJ. Timeliness of entry to lung most cancers prognosis and remedy: a scoping literature assessment. Lung Most cancers. 2017;112:156–64.
Cao M, Chen W. Epidemiology of lung most cancers in China. Thorac Most cancers. 2019;10:3–7.
Witwer KW, Buzas EI, Bemis LT, Bora A, Lasser C, Lotvall J, Nolte-’t Hoen EN, Piper MG, Sivaraman S, Skog J, et al. Standardization of pattern assortment, isolation and evaluation strategies in extracellular vesicle analysis. J Extr Vesicles. 2013. https://doi.org/10.3402/jev.v2i0.20360.
Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and different extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.
Yan G, Xiao Q, Zhao J, Chen H, Xu Y, Tan M, Peng L. Brucea javanica derived exosome-like nanovesicles ship miRNAs for most cancers remedy. J Management Launch. 2024;367:425–40.
Peng LH, Wang MZ, Chu Y, Zhang L, Niu J, Shao HT, Yuan TJ, Jiang ZH, Gao JQ, Ning XH. Engineering bacterial outer membrane vesicles as transdermal nanoplatforms for photo-TRAIL-programmed remedy in opposition to melanoma. Sci Adv. 2020;6:eaba735.
Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L. Intercellular switch of exosomal wild kind EGFR triggers osimertinib resistance in non-small cell lung most cancers. Mol Most cancers. 2021;20:17.
Muluhngwi P, Valdes R Jr, Fernandez-Botran R, Burton E, Williams B, Linder MW. Cell-free DNA diagnostics: present and rising functions in oncology. Pharmacogenomics. 2019;20:357–80.
Sheridan C. Exosome most cancers diagnostic reaches market. Nat Biotechnol. 2016;34:359–60.
Dad HA, Gu TW, Zhu AQ, Huang LQ, Peng LH. Plant exosome-like nanovesicles: rising therapeutics and drug supply nanoplatforms. Mol Ther. 2021;29:13–31.
Fernandes M, Lopes I, Teixeira J, Botelho C, Gomes AC. Exosome-like nanoparticles: a brand new kind of nanocarrier. Curr Med Chem. 2020;27:3888–905.
Radler J, Gupta D, Zickler A, Andaloussi SE. Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading. Mol Ther. 2023;31:1231–50.
Zhu L, Solar HT, Wang S, Huang SL, Zheng Y, Wang CQ, Hu BY, Qin W, Zou TT, Fu Y, et al. Isolation and characterization of exosomes for most cancers analysis. J Hematol Oncol. 2020;13:152.
Genschmer KR, Russell DW, Lal C, Szul T, Bratcher PE, Noerager BD, Abdul Roda M, Xu X, Rezonzew G, Viera L, et al. Activated PMN exosomes: pathogenic entities inflicting matrix destruction and illness within the lung. Cell. 2019;176(113–126): e115.
Li MY, Liu LZ, Dong M. Progress on pivotal function and utility of exosome in lung most cancers carcinogenesis, prognosis, remedy and prognosis. Mol Most cancers. 2021;20:22.
Christ L, Raiborg C, Wenzel EM, Campsteijn C, Stenmark H. Mobile capabilities and molecular mechanisms of the ESCRT membrane-scission equipment. Traits Biochem Sci. 2017;42:42–56.
van Niel G, D’Angelo G, Raposo G. Shedding gentle on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213–28.
Kalluri R, LeBleu VS. The biology, operate, and biomedical functions of exosomes. Science. 2020;367:6478.
Xu XH, Yuan TJ, Dad HA, Shi MY, Huang YY, Jiang ZH, Peng LH. Plant exosomes as novel nanoplatforms for MicroRNA switch stimulate neural differentiation of stem cells in vitro and in vivo. Nano Lett. 2021;21:8151–9.
Solar W, Ren Y, Lu Z, Zhao X. The potential roles of exosomes in pancreatic most cancers initiation and metastasis. Mol Most cancers. 2020;19:135.
McAndrews KM, Kalluri R. Mechanisms related to biogenesis of exosomes in most cancers. Mol Most cancers. 2019;18:52.
Wu M, Wang G, Hu W, Yao Y, Yu XF. Rising roles and therapeutic worth of exosomes in most cancers metastasis. Mol Most cancers. 2019;18:53.
Zha QB, Yao YF, Ren ZJ, Li XJ, Tang JH. Extracellular vesicles: an outline of biogenesis, operate, and function in breast most cancers. Tumour Biol. 2017;39:1010428317691182.
Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B, Xie Y, Ye Y, Liu J. Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by focusing on LMO7. J Cell Mol Med. 2017;21:1228–36.
Zhang X, Sai B, Wang F, Wang L, Wang Y, Zheng L, Li G, Tang J, Xiang J. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung most cancers cells by way of STAT3-induced EMT. Mol Most cancers. 2019;18:40.
Rm A. Lung most cancers exosomes as drivers of epithelial mesenchymal transition. Oncotarget. 2016;7:54852–66.
Zhou Y, Zhang Y, Xu J, Wang Y, Yang Y, Wang W, Gu A, Han B, Shurin GV, Zhong R, et al. Schwann cell-derived exosomes promote lung most cancers development by way of miRNA-21-5p. Glia. 2024;72:692–707.
Zhang N, Nan A, Chen L, Li X, Jia Y, Qiu M, Dai X, Zhou H, Zhu J, Zhang H, Jiang Y. Round RNA circSATB2 promotes development of non-small cell lung most cancers cells. Mol Most cancers. 2020;19:101.
Zhang F, Jiang JJ, Qian H, Yan YM, Xu WR. Exosomal circRNA: rising insights into most cancers development and scientific utility potential. J Hematol Oncol. 2023. https://doi.org/10.1186/s13045-023-01452-2.
Liang M, Chen X, Wang L, Qin L, Wang H, Solar Z, Zhao W, Geng B. Most cancers-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to advertise lung most cancers development. J Exp Clin Most cancers Res. 2020;39:176.
Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in most cancers metastasis and drug resistance. Mol Most cancers. 2019;18:75.
Kholia S, Ranghino A, Garnieri P, Lopatina T, Deregibus MC, Rispoli P. Extracellular vesicles as new gamers in angiogenesis. Vasc Pharmacol. 2016;86:64–70.
Yang H, Zhang H, Ge S, Ning T, Bai M, Li J, Li S, Solar W, Deng T, Zhang L, et al. RETRACTED: exosome-derived miR-130a prompts angiogenesis in gastric most cancers by focusing on C-MYB in vascular endothelial cells. Mol Ther. 2018;26:2466–75.
Hsu YL, Hung JY, Chang WA, Lin YS, Pan YC, Tsai PH, Wu CY, Kuo PL. Hypoxic lung cancer-secreted exosomal miR-23a elevated angiogenesis and vascular permeability by focusing on prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017;36:4929–42.
Wilson CM, Naves T, Vincent F, Melloni B, Bonnaud F, Lalloue F, Jauberteau MO. Sortilin mediates the discharge and switch of exosomes in live performance with two tyrosine kinase receptors. J Cell Sci. 2014;127:3983–97.
Weidle UH, Birzele F, Kollmorgen G, Ruger R. The a number of roles of exosomes in metastasis. Most cancers Genomics Proteomics. 2017;14:1–15.
Arneth B. Tumor Microenvironment. Medicina (Kaunas). 2019;56:15.
Xu Z, Chen Y, Ma L, Chen Y, Liu J, Guo Y, Yu T, Zhang L, Zhu L, Shu Y. Function of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages within the tumor microenvironment. Mol Ther. 2022;30:3133–54.
Yang E, Wang X, Gong Z, Yu M, Wu H, Zhang D. Exosome-mediated metabolic reprogramming: the rising function in tumor microenvironment transforming and its affect on most cancers development. Sign Transduct Goal Ther. 2020;5:242.
Petanidis S, Domvri Ok, Porpodis Ok, Anestakis D, Freitag L, Hohenforst-Schmidt W, Tsavlis D, Zarogoulidis Ok. Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression by way of RIP-3 dependent necroptosis and miR-146/miR-210 modulation. Biomed Pharmacother. 2020;122: 109461.
Lobb RJ, Lima LG, Moller A. Exosomes: key mediators of metastasis and pre-metastatic area of interest formation. Semin Cell Dev Biol. 2017;67:3–10.
Whiteside TL. Tumor-derived exosomes and their function in tumor-induced immune suppression. Vaccines. 2016;4:35.
Pyzer AR, Cole L, Rosenblatt J, Avigan DE. Myeloid-derived suppressor cells as effectors of immune suppression in most cancers. Int J Most cancers. 2016;139:1915–26.
Boyang L. Exosome-derived microRNA-433 inhibits tumorigenesis via incremental infiltration of CD4 and CD8 cells in non-small cell lung most cancers. Oncol Lett. 2021;22:607–607.
Huang SH, Li Y, Zhang J, Rong J, Ye S. Epidermal progress issue receptor-containing exosomes induce tumor-specific regulatory T cells. Most cancers Make investments. 2013;31:330–5.
Seigo Ok. al e: MicroRNA-200b is a possible biomarker of the expression of PD-L1 in sufferers with lung most cancers. Thoracic most cancers. 2020;11:2975–82.
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S, Committee EG. Early and domestically superior non-small-cell lung most cancers (NSCLC): ESMO Scientific Apply Pointers for prognosis, remedy and follow-up. Ann Oncol. 2017;28:iv1–21.
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L. Lung most cancers: present therapies and new focused therapies. Lancet. 2017;389:299–311.
Kong F, Wang C, Zhao L, Liao D, Wang X, Solar B, Yang P, Jia Y. Conventional Chinese language medicines for non-small cell lung most cancers: therapies and mechanisms. Chin Herb Med. 2023;15:509–15.
Nam GH, Choi Y, Kim GB, Kim S, Kim SA, Kim IS. Rising prospects of exosomes for most cancers remedy: from standard remedy to immunotherapy. Adv Mater. 2020. https://doi.org/10.1002/adma.202002440.
Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, Kim HR, Lee JH, Kim S, Cho BC. Subsequent-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung most cancers with acquired resistance to EGFR-TKIs. Lung Most cancers. 2017;113:106–14.
Zhu L, Li J, Gong YL, Wu QB, Tan SY, Solar D, Xu XM, Zuo YL, Zhao Y, Wei YQ, et al. Exosomal tRNA-derived small RNA as a promising biomarker for most cancers prognosis. Mol Most cancers. 2019. https://doi.org/10.1186/s12943-019-1000-8.
Yang Q, Cheng L, Hu L, Lou D, Zhang T, Li J, Zhu Q, Liu F. An integrative microfluidic machine for isolation and ultrasensitive detection of lung cancer-specific exosomes from affected person urine. Biosens Bioelectron. 2020;163: 112290.
Shin H, Choi BH, Shim O, Kim J, Park Y, Cho SK, Kim HK, Choi Y. Single test-based prognosis of a number of most cancers sorts utilizing Exosome-SERS-AI for early stage cancers. Nat Commun. 2023;14:1644.
Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, Fang X, Zhang X. Exosomes as a brand new frontier of most cancers liquid biopsy. Mol Most cancers. 2022;21:56.
Yoneyama T, Gorry M, Sobo-Vujanovic A, Lin Y, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, et al. ADAM10 sheddase exercise is a possible lung-cancer biomarker. J Most cancers. 2018;9:2559–70.
Kim DH, Park H, Choi YJ, Im Ok, Lee CW, Kim D, Pack CG, Kim HY, Choi CM, Lee JC, et al. Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung most cancers. Biomark Res. 2023;11:80.
Marco G. Exosomal miRNA evaluation in Non-small Cell Lung Most cancers (NSCLC) sufferers’ plasma via qPCR: a possible liquid biopsy Device. J Vis Exp. 2016;27(111):53900.
Wang DL, Wang S, Jin MM, Zuo Y, Wang JP, Niu Y, Zhou Q, Chen JW, Tang XR, Tang WX, et al. Hypoxic exosomal circPLEKHM1-mediated crosstalk between tumor cells and macrophages drives lung most cancers metastasis. Adv Sci. 2024. https://doi.org/10.1002/advs.202309857.
Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, Tang XM, Solar F, Lu HM, Deng J, et al. Liquid biopsy in lung most cancers: significance in diagnostics, prediction, and remedy monitoring. Mol Most cancers. 2022;21:25.
Wang MZ, Yan G, Xiao QY, Zhou N, Chen HR, Xia W, Peng LH. Iontophoresis-driven microneedle arrays delivering transgenic outer membrane vesicles in program that stimulates transcutaneous vaccination for most cancers immunotherapy. Small Sci. 2023;3:2300126.
Fabbri MPA, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012;109:E2110–6.
Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removing as a therapeutic adjuvant in most cancers. J Transl Med. 2012;10:134.
Fu WY, Lei CH, Liu SW, Cui YS, Wang CQ, Qian KW, Li T, Shen YF, Fan XY, Lin FX, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour results and low toxicity. Nat Commun. 2019;10:4355.
Mangiapane G, Parolini I, Conte Ok, Malfatti MC, Corsi J, Sanchez M, Pietrantoni A, D’Agostino VG, Inform G. Enzymatically energetic apurinic/apyrimidinic endodeoxyribonuclease 1 is launched by mammalian cells via exosomes. J Biol Chem. 2021;296: 100569.
Wang JL, Wang LM, Lin ZD, Tao LS, Chen M. Extra environment friendly induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells. Mol Med Rep. 2014;9:125–31.
Yan Y, Du C, Duan X, Yao X, Wan J, Jiang Z, Qin Z, Li W, Pan L, Gu Z, et al. Inhibiting collagen I manufacturing and tumor cell colonization within the lung by way of miR-29a-3p loading of exosome-/liposome-based nanovesicles. Acta Pharm Sin B. 2022;12:939–51.
Wu HB, Mu XQ, Liu L, Wu HJ, Hu XF, Chen LJ, Liu J, Mu Y, Yuan FF, Liu WJ, Zhao YQ. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung most cancers cells by way of focusing on LRRC1. Cell Loss of life Dis. 2020;11:801.
Xie H, Wang J. MicroRNA-320a-containing exosomes from human umbilical twine mesenchymal stem cells curtail proliferation and metastasis in lung most cancers by binding to SOX4. J Recept Sign Transd. 2022;42:268–78.
Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, Han MK, Xiao B, Xu C, Srinivasan S, Merlin D. Edible ginger-derived nanoparticles: a novel therapeutic strategy for the prevention and remedy of inflammatory bowel illness and colitis-associated most cancers. Biomaterials. 2016;101:321–40.
Raimondo S, Naselli F, Fontana S, Monteleone F, Lo Dico A, Saieva L, Zito G, Flugy A, Manno M, Di Bella MA, et al. Citrus limon-derived nanovesicles inhibit most cancers cell proliferation and suppress CML xenograft progress by inducing TRAIL-mediated cell loss of life. Oncotarget. 2015;6:19514–27.
Chen Q, Li Q, Liang Y, Zu M, Chen N, Canup BSB, Luo L, Wang C, Zeng L, Xiao B. Pure exosome-like nanovesicles from edible tea flowers suppress metastatic breast most cancers by way of ROS era and microbiota modulation. Acta Pharm Sin B. 2022;12:907–23.
Kim J, Zhu Y, Chen S, Wang D, Zhang S, Xia J, Li S, Qiu Q, Lee H, Wang J. Anti-glioma impact of ginseng-derived exosomes-like nanoparticles by energetic blood-brain-barrier penetration and tumor microenvironment modulation. J Nanobiotechnol. 2023;21:253.
Wang QL, Zhuang XY, Mu JY, Deng ZB, Jiang H, Zhang LF, Xiang XY, Wang BM, Yan J, Miller D, Zhang HG. Supply of therapeutic brokers by nanoparticles made from grapefruit-derived lipids. Nat Commun. 2016;7:11347.
Fitts CA, Ji N, Li Y, Tan C. Exploiting exosomes in most cancers liquid biopsies and drug supply. Adv Healthc Mater. 2019;8: e1801268.
Xie H, Yao J, Wang Y, Ni B. Exosome-transmitted circVMP1 facilitates the development and cisplatin resistance of non-small cell lung most cancers by focusing on miR-524-5p-METTL3/SOX2 axis. Drug Deliv. 2022;29:1257–71.
Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A. Membrane microparticles mediate switch of P-glycoprotein to drug delicate most cancers cells. Leukemia. 2009;23:1643–9.
Hassanzadeh A, Rahman HS, Markov A, Endjun JJ, Zekiy AO, Chartrand MS, Beheshtkhoo N, Kouhbanani MAJ, Marofi F, Nikoo M, Jarahian M. Mesenchymal stem/stromal cell-derived exosomes in regenerative medication and most cancers; overview of improvement, challenges, and alternatives. Stem Cell Res Ther. 2021;12:297.
Yang G, Zhang W, Yu C, Ren J, An Z. MicroRNA let-7: Regulation, single nucleotide polymorphism, and remedy in lung most cancers. J Most cancers Res Ther. 2015;11(Suppl 1):C1-6.
Delong L, Debin M, Rungui N. Exosome-reversed chemoresistance to cisplatin in non-small lung most cancers via transferring miR-613. Most cancers Handle Res. 2020;12:7961–72.
Zhou W, Dong M, Wu H, Li HL, Xie JL, Ma RY, Su WW, Dai JY. Widespread mechanism of Citrus Grandis Exocarpium in remedy of power obstructive pulmonary illness and lung most cancers. Chin Herb Med. 2021;13:525–33.
Ma BN, Li XJ. Resveratrol extracted from Chinese language natural medicines: a novel therapeutic technique for lung ailments. Chin Herb Med. 2020;12:349–58.
Tan MH, Liu YD, Xu Y, Yan G, Zhou N, Chen HR, Jiang ZH, Peng LH. Plant-derived exosomes as novel nanotherapeutics contrive glycolysis reprogramming-mediated angiogenesis for diabetic ulcer therapeutic. Biomater Res. 2024;28:0035.
Perut F, Roncuzzi L, Avnet S, Massa A, Zini N, Sabbadini S, Giampieri F, Mezzetti B, Baldini N. Strawberry-derived exosome-like nanoparticles stop oxidative stress in human mesenchymal stromal cells. Biomolecules. 2021;11(1):87.
Rutter BD, Innes RW. Extracellular vesicles remoted from the leaf apoplast carry stress-response proteins. Plant Physiol. 2017;173:728–41.
Teng Y, Ren Y, Sayed M, Hu X, Lei C, Kumar A, Hutchins E, Mu JY, Deng ZB, Luo C, et al. Plant-derived exosomal MicroRNAs form the intestine microbiota. Cell Host Microbe. 2018;24:637-652.e638.
Zhou LK, Zhou Z, Jiang XM, Zheng Y, Chen X, Fu Z, Xiao G, Zhang CY, Zhang LK, Yi Y. Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the unfavorable conversion of contaminated sufferers. Cell Discov. 2020;6:54.
Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H, Xiang X, Deng ZB, Wang B, Zhang L, et al. Grape exosome-like nanoparticles induce intestinal stem cells and shield mice from DSS-induced colitis. Mol Ther. 2013;21:1345–57.
Bruno SP, Paolini A, D’Oria V, Sarra A, Sennato S, Bordi F, Masotti A. Extracellular vesicles derived from citrus sinensis modulate inflammatory genes and tight junctions in a human mannequin of intestinal epithelium. Entrance Nutr. 2021;8: 778998.
Zhao Q, Wang T, Wang H, Cao P, Jiang C, Qiao H, Peng L, Lin X, Jiang Y, Jin H, et al. Consensus assertion on analysis and utility of Chinese language natural medication derived extracellular vesicles-like particles (2023 version). Chin Herb Med. 2024;16:3–12.
Rezaie J, Feghhi M, Etemadi T. A assessment on exosomes utility in scientific trials: perspective, questions, and challenges. Cell Commun Sign. 2022;20:145.
Chen YS, Lin EY, Chiou TW, Harn HJ. Exosomes in scientific trial and their manufacturing in compliance with good manufacturing follow. Tzu Chi Med J. 2020;32:113–20.
Chin AR, Fong MY, Somlo G, Wu J, Swiderski P, Wu X, Wang SE. Cross-kingdom inhibition of breast most cancers progress by plant miR159. Cell Res. 2016;26:217–28.
Maitra S, Sarkar S, Dhara B. Modified plant-derived exosomes: precision medication in most cancers remedy. Clin Transl Discov. 2024. https://doi.org/10.1002/ctd2.338.
Amiri A, Pourhanifeh MH, Mirzaei HR, Nahand JS, Moghoofei M, Sahebnasagh R, Mirzaei H, Hamblin MR. Exosomes and lung most cancers: roles in pathophysiology, prognosis and therapeutic functions. Curr Med Chem. 2021;28:308–28.
Riazifar M, Mohammadi MR, Pone EJ, Yeri A, Lässer C, Segaliny AI, McIntyre LL, Shelke GV, Hutchins E, Hamamoto A, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative issues. ACS Nano. 2019;13:6670–88.
Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, Shen B, Liu S, Yan D, Feng J. Cisplatin-resistant lung most cancers cell-derived exosomes improve cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent method. Int J Nanomed. 2017;12:3721–33.
Jing C, Cao H, Qin X, Yu S, Wu J, Wang Z, Ma R, Feng J. Exosome-mediated gefitinib resistance in lung most cancers HCC827 cells by way of supply of miR-21. Oncol Lett. 2018;15:9811–7.
Riazifar M, Mohammadi MR, Pone EJ, Yeri A, Lasser C, Segaliny AI. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative issues. ACS Nano. 2019;13:6670–88.
Shahabipour F, Barati N, Johnston TP, Derosa G, Maffioli P, Sahebkar A. Exosomes: nanoparticulate instruments for RNA interference and drug supply. J Cell Physiol. 2017;232:1660–8.
Gordon-Alonso M, Yanez-Mo M, Barreiro O, Alvarez S, Munoz-Fernandez MA, Valenzuela-Fernandez A, Sanchez-Madrid F. Tetraspanins CD9 and CD81 modulate HIV-1-induced membrane fusion. J Immunol. 2006;177:5129–37.
Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, Osobamiro O, Shu W, Jiang F, Chopp M. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma progress. Most cancers Lett. 2013;335:201–4.
Ohno S, Takanashi M, Sudo Ok, Ueda S, Ishikawa A, Matsuyama N, Fujita Ok, Mizutani T, Ohgi T, Ochiya T, et al. Systemically injected exosomes focused to EGFR ship antitumor MicroRNA to breast most cancers cells. Mol Ther. 2013;21:185–91.
Liu M, Hu S, Yan N, Popowski KD, Cheng Ok. Inhalable extracellular vesicle supply of IL-12 mRNA to deal with lung most cancers and promote systemic immunity. Nat Nanotechnol. 2024;19(4):565–75.
Nie H, Xie X, Zhang D, Zhou Y, Li B, Li F, Li F, Cheng Y, Mei H, Meng H, Jia L. Use of lung-specific exosomes for miRNA-126 supply in non-small cell lung most cancers. Nanoscale. 2020;12:877–87.
Zhu T, Chen Z, Jiang G, Huang X. Sequential focusing on hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced most cancers immunochemotherapy. ACS Nano. 2023;17:16770–86.
Gao J, Wang S, Wang Z. Excessive yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation remedy. Biomaterials. 2017;135:62–73.
Kim MS, Haney MJ, Zhao Y, Yuan D, et al. Engineering macrophage-derived exosomes for focused paclitaxel supply to pulmonary metastases: in vitro and in vivo evaluations. Nanomed Nanotechnol Biol Med. 2018;14:195–204.
Wang C, Li N, Li Y, Hou S, Zhang W, Meng Z, Wang S, Jia Q, Tan J, Wang R, Zhang R. Engineering a HEK-293T exosome-based supply platform for environment friendly tumor-targeting chemotherapy/inner irradiation mixture remedy. J Nanobiotechnology. 2022;20:247.
Tian Y, Li S, Music J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G. A doxorubicin supply platform utilizing engineered pure membrane vesicle exosomes for focused tumor remedy. Biomaterials. 2014;35:2383–90.
Srivastava A, Amreddy N, Babu A, Panneerselvam J, Mehta M, Muralidharan R, Chen A, Zhao YD, Razaq M, Riedinger N, et al. Nanosomes carrying doxorubicin exhibit potent anticancer exercise in opposition to human lung most cancers cells. Sci Rep. 2016;6:38541.
Li YJ, Wu JY, Wang JM, Hu XB, Cai JX, Xiang DX. Gemcitabine loaded autologous exosomes for efficient and secure chemotherapy of pancreatic most cancers. Acta Biomater. 2020;101:519–30.
Kim G, Lee Y, Ha J, Han S, Lee M. Engineering exosomes for pulmonary supply of peptides and medicines to inflammatory lung cells by inhalation. J Management Launch. 2021;330:684–95.
Zheng W, Zhu TC, Tang LT, Li ZJ, Jiang GM, Huang X. Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung most cancers. J Transl Med. 2023;21:383.
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wooden MJ. Supply of siRNA to the mouse mind by systemic injection of focused exosomes. Nat Biotechnol. 2011;29:341–5.
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Most cancers. 2006;6:857–66.
Akao Y, Iio A, Itoh T, Noguchi S, Itoh Y, Ohtsuki Y, Naoe T. Microvesicle-mediated RNA molecule supply system utilizing monocytes/macrophages. Mol Ther. 2011;19:395–9.
Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular switch of MicroRNAs in dwelling cells. J Biol Chem. 2010;285:17442–52.
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesik F, Laplanche A, et al. Dendritic cell-derived exosomes as upkeep immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016. https://doi.org/10.1080/2162402X.2015.1071008.
He W, Zheng S, Zhang H, Gao B, Jin J, Zhang M, He Q. Plant-derived vesicle-like nanoparticles: scientific utility exploration and challenges. Int J Nanomed. 2023;18:5671–83.
Sarasati A, Syahruddin MH, Nuryanti A, Ana ID, Barlian A, Wijaya CH, Ratnadewi D, Wungu TDK, Takemori H. Plant-derived exosome-like nanoparticles for biomedical functions and regenerative remedy. Biomedicines. 2023;11(4):1053.
Xu Y, Yan G, Zhao JY, Ren YH, Xiao QY, Tan MH, Peng LH. Plant-derived exosomes as cell homogeneous nanoplatforms for mind biomacromolecules supply ameliorate mitochondrial dysfunction in opposition to Parkinson’s illness. Nano At this time. 2024;58:102438.
